Global Anthrax Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 190 pages | ID: G3C9EA9CBACEN
Precision Business Insights (PBI)

Abstracts

Anthrax Vaccine Market

Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. Global anthrax market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the anthrax vaccine market.

Global anthrax vaccine market is segmented based on the type of vaccine, end user and geographical regions.

On the basis of type of vaccine, anthrax vaccine market is segmented as

• Live Vaccines
• Cell free PA Vaccines

On basis of end user, anthrax vaccine market is segmented as

• Hospitals
• Clinics
• Vaccination Centres
• Others

The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.

Geographically, Global anthrax vaccine is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. The presence of various ongoing programs under the organizations such as BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors for the revenue generation in North America region. Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. The extensive vaccine manufacturing facilities across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position.

Some of the players in the anthrax vaccines market are Emergent BioSolutions (US), Elusys Therapeutics (US), Porton Biopharma Limited (UK), and Panacea Biotec (India) to name a few.

In 2015, Emergent BioDefense Operations Lansing LLC received U.S. FDA approval for its BioThrax, a vaccine for Anthrax.

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ANTHRAX MARKET INTRODUCTION

2.1. Global Anthrax Market – Taxonomy
2.2. Global Anthrax Market –Definitions
  2.2.1. Type of vaccine
  2.2.2. End User

3. GLOBAL ANTHRAX MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anthrax Market Dynamics – Factors Impact Analysis
3.6. Global Anthrax Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Anthrax Market – Product Innovations

4. GLOBAL ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ANTHRAX MARKET, BY TYPE OF VACCINE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Live Vaccine
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Cell Free PA Vaccine
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis

6. GLOBAL ANTHRAX MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospitals
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Clinics
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Vaccination Centres
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.4.3. Market Opportunity Analysis

7. GLOBAL ANTHRAX MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.5.3. Market Opportunity Analysis
7.6. Global Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2017 – 2023

8. NORTH AMERICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  8.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    8.1.1.1. Live Vaccines
    8.1.1.2. Cell free PA Vaccines
  8.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    8.1.2.1. Hospitals
    8.1.2.2. Clinics
    8.1.2.3. Vaccination Centres
    8.1.2.4. Others
  8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    8.1.3.1. U.S.
    8.1.3.2. Canada
  8.1.4. North America Anthrax Market - Opportunity Analysis Index, By Type of vaccine, End User and Country, 2017 – 2023
  8.1.5. North America Anthrax Market Dynamics – Trends

9. EUROPE ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Live Vaccines
    9.1.1.2. Cell free PA Vaccines
  9.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Hospitals
    9.1.2.2. Clinics
    9.1.2.3. Vaccination Centres
    9.1.2.4. Others
  9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Germany
    9.1.3.2. UK
    9.1.3.3. France
    9.1.3.4. Spain
    9.1.3.5. Italy
    9.1.3.6. Russia
    9.1.3.7. Poland
    9.1.3.8. Rest of Europe
  9.1.4. Europe Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End user and Country, 2017 – 2023
  9.1.5. Europe Anthrax Market Dynamics – Trends

10. ASIA-PACIFIC ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Live Vaccines
    10.1.1.2. Cell free PA Vaccines
  10.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Hospitals
    10.1.2.2. Clinics
    10.1.2.3. Vaccination Centres
    10.1.2.4. Others
  10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    10.1.3.1. Japan
    10.1.3.2. China
    10.1.3.3. India
    10.1.3.4. ASEAN
    10.1.3.5. Australia & New Zealand
    10.1.3.6. Rest of Asia-Pacific
  10.1.4. Asia-Pacific Anthrax Market - Opportunity Analysis Index, By Type of vaccine, End-User and Country, 2017 – 2023
  10.1.5. Europe Anthrax Market Dynamics – Trends

11. LATIN AMERICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Live Vaccines
    11.1.1.2. Cell free PA Vaccines
  11.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Hospitals
    11.1.2.2. Clinics
    11.1.2.3. Vaccination Centres
    11.1.2.4. Others
  11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Brazil
    11.1.3.2. Mexico
    11.1.3.3. Argentina
    11.1.3.4. Venezuela
    11.1.3.5. Rest of Latin America
  11.1.4. Latin America Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End User and Country, 2017 – 2023
  11.1.5. Latin America Anthrax Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Live Vaccines
    12.1.1.2. Cell free PA Vaccines
  12.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Hospitals
    12.1.2.2. Clinics
    12.1.2.3. Vaccination Centres
    12.1.2.4. Others
  12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.3.1. Gulf Cooperation Council (GCC) Countries
    12.1.3.2. Israel
    12.1.3.3. South Africa
    12.1.3.4. Rest of MEA
  12.1.4. MEA Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End-User and Country, 2017 – 2023
  12.1.5. MEA Anthrax Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Emergent BioSolutions (U.S)
  13.2.2. Elusys Therapeutics (U.S.)
  13.2.3. Porton Biopharma Limited (UK)
  13.2.4. Panacea Biotec (India)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS